Paloma Partners’s ADMA Biologics ADMA Stock Holding History

Paloma Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-39,600	Closed	-$116K	–	2023
2020 Q2	$116K	Buy	+39,600	New	+$114K	﹤0.01%	1868

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's ADMA Position: Q3 2020 in Review

Paloma Partners sold out of ADMA Biologics (ADMA) in Q3 2020, closing a stake of 39,600 shares — an estimated $116K sold.

Paloma Partners first reported a position in ADMA in Q2 2020 and held it in 1 quarter. The position peaked at $116K in Q2 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q3 2020.

Paloma Partners reported no remaining ADMA Biologics position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 39,600 ADMA Biologics shares in Q3 2020, an estimated $116K.
Paloma Partners first reported a position in ADMA Biologics in Q2 2020 and held it in 1 quarter.
Paloma Partners's ADMA Biologics position peaked at $116K in Q2 2020.
95 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.